Research programme: janus kinase inhibitor - CJ HealthcareAlternative Names: JAK inhibitor - CJ Healthcare
Latest Information Update: 20 Jun 2016
$50 / €47 *
At a glance
- Originator CJ Cheiljedang Corp.
- Developer CJ HealthCare
- Mechanism of Action Janus kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 01 Jan 2016 Preclinical trials in Rheumatoid arthritis in South Korea (unspecified route)